

**APPIC (2016-719)**

**SERIOUS ADVERSE EVENT REPORT**

Mail all pages of the reports to: [sae.invent.ctc@erasmusmc.nl](mailto:sae.invent.ctc@erasmusmc.nl), fax +31 (0)10 70 41 028

<b>Patient information</b>	<i>CTC staff only</i>
Patient study number	SAE sequence number
Year of birth	Report reviewed by
	Date review

**Report information**

Hospital

Person reporting the SAE

Type of report  Initial report  Follow up report  Final report

Date of initial report [dd/mm/yyyy]

Date of follow up report [dd/mm/yyyy]

Date of final report [dd/mm/yyyy]

**Serious Adverse Event information**

Adverse Event Term

Diagnosis of Adverse Event in a single term; if no diagnosis is available yet, please provide the most relevant sign or symptom

Date onset AE [dd/mm/yyyy]

Date AE became Serious [dd/mm/yyyy]

Reason AE is Serious

1= death    2= life-threatening    3= (prolongation of) hospitalization  
4= significant / persistent disability    5= congenital anomaly / birth defect  
6= other medically important condition

Date of hospitalization [dd/mm/yyyy]

Date of discharge [dd/mm/yyyy]

Severity of AE [CTCAE grade]

(Highest grade observed)

**SAE description and comments** - describe the course of events, include dates and results of tests / procedures / actions taken /dates of discharge (for final report: outcome of adverse event, test result etc.)

.....

.....

.....

.....

.....

.....

.....

.....

**Treatment Arm and Phase**

Treatment arm

Protocol phase during / after which the SAE occurred

1= arm A (short 48 hours course of intravenous antibiotics)  
2= arm B (standard 5 days course of intravenous antibiotics)  
0= Postoperative, before discharge  
1= Postoperative, after discharge

**APPIC (2016-719)**

**SERIOUS ADVERSE EVENT REPORT**

Mail all pages of the reports to: [sae.invent.ctc@erasmusmc.nl](mailto:sae.invent.ctc@erasmusmc.nl), fax +31 (0)10 70 41 028

Pat. Study number: |\_|\_|\_|\_|\_| Date of report |\_|||\_|\_|\_|\_|\_|

Initial report  Follow up report  Final report

**Trial medication**

Please specify details of the trial medication/treatment that the patient received in this protocol phase:

Trial medication <sup>1</sup>	Total daily dose (please add units)	Date first administration (during this protocol phase)	Date last administration (Date last dose prior to SAE)	Relationship to SAE <sup>2</sup>	Action taken as a result of this SAE <sup>3</sup>
_	.....	_   _ _ _ _ _	_   _ _ _ _ _	_	_
_	.....	_   _ _ _ _ _	_   _ _ _ _ _	_	_
_	.....	_   _ _ _ _ _	_   _ _ _ _ _	_	_

<sup>1</sup> Trial medication		<sup>2</sup> Relationship to SAE	<sup>3</sup> Action taken	
0= Not applicable	2= Cefuroxim	0= unrelated	0= none	3= interrupted
1= Metronidazol	3= Ceftriaxon	1= likely	1= next dose reduced	4= discontinued
			2= delayed	5= restarted

**Possible Causes of SAE other than Trial medication**

Please specify if there are circumstances other than trial medication that may have contributed to the SAE or could help explain the SAE

Disease under study (including progression) |\_| 0= No 1= Yes

Medical condition(s) |\_| 0= No 1= Yes, specify below  
*Any relevant past or current medical disorders (not disease under study), allergies, surgeries that could help explain the SAE*

Concomitant medication(s) |\_| 0= No 1= Yes, specify below

Other |\_| 0= No 1= Yes, specify below

Specification:.....  
 .....  
 .....

**Outcome of SAE**

|\_| 1= resolved\*  
 2= ongoing  
 3= death (caused by SAE)\*\*  
 4= ongoing at death (death due to another cause)\*\*  
 5= ongoing closed (because stable situation reached)

\* Date SAE resolved [dd/mm/yyyy] |\_|||\_|\_|\_|\_|\_|

\*\* Date of death [dd/mm/yyyy] |\_|||\_|\_|\_|\_|\_|

\*\* Cause of death .....

Action taken regarding the SAE .....

**Signature for report** – the (sub) investigator should always review and sign at least the final report

Date |\_|||\_|\_|\_|\_|\_| Name: ..... Signature .....

Date |\_|||\_|\_|\_|\_|\_| Name: ..... Signature .....

Date |\_|||\_|\_|\_|\_|\_| Name: ..... Signature .....

Date |\_|||\_|\_|\_|\_|\_| Name: ..... Signature .....

Date |\_|||\_|\_|\_|\_|\_| Name: ..... Signature .....